Home › Funds › Capital Research Global Investors › ABBV
Capital Research Global Investors position in ABBV
ABBVIE INC · Health Care
Capital Research Global Investors reported holding 31,115,872 shares of ABBV (ABBVIE INC) in its Q3 2026 13F filing — a position valued at US$8.14B, representing 1.17% of its reported portfolio and ranking #20 among its reported holdings. Capital Research Global Investors has disclosed ABBV holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Capital Research Global Investors's ABBV position evolved
Capital Research Global Investors first disclosed a stake in ABBV in Q3 2023 at 31,976,144 shares (US$4.77B). The position peaked in Q3 2026 at 31,115,872 shares, worth US$8.14B. Across 13 filings, Capital Research Global Investors increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 31,115,872 shares valued at US$8.14B — an increase of 1,014,321 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 31.98M | $4.77B | New |
| Q4 2023 | 30.30M | $4.70B | Reduce |
| Q1 2024 | 31.30M | $5.70B | Add |
| Q2 2024 | 33.19M | $5.69B | Add |
| Q3 2024 | 33.21M | $6.56B | Hold |
| Q4 2024 | 33.98M | $6.04B | Add |
| Q1 2025 | 33.51M | $7.02B | Reduce |
| Q2 2025 | 25.27M | $4.69B | Reduce |
| Q3 2025 | 25.23M | $5.84B | Hold |
| Q4 2025 | 25.41M | $5.81B | Add |
| Q1 2026 | 31.25M | $6.80B | Add |
| Q2 2026 | 30.10M | $7.57B | Reduce |
| Q3 2026 | 31.12M | $8.14B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABBV and 13F data
ABBV (ABBVIE INC) is a Health Care company. 30 other funds we track also report a position in ABBV — the largest reported positions include Vanguard Group (US$41.31B), BlackRock Inc (US$37.62B), VANGUARD CAPITAL MANAGEMENT LLC (US$30.26B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABBV
- Vanguard Group 180.78M sh · $41.31B · Q4 2025
- BlackRock Inc 149.49M sh · $37.62B · Q2 2026
- VANGUARD CAPITAL MANAGEMENT LLC 115.68M sh · $30.26B · Q3 2026
- STATE STREET CORP 82.82M sh · $21.66B · Q3 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC 49.00M sh · $12.82B · Q3 2026
- Geode Capital Management 47.50M sh · $12.40B · Q3 2026
- GEODE CAPITAL MANAGEMENT, LLC 47.00M sh · $11.81B · Q2 2026
- Morgan Stanley 38.90M sh · $9.79B · Q2 2026
- Capital Research Global Investors 30.10M sh · $7.57B · Q2 2026
- Norges Bank Investment Management 25.55M sh · $6.43B · Q2 2026
- Franklin Resources 19.70M sh · $5.81B · Q3 2026
- Capital World Investors 20.65M sh · $5.40B · Q3 2026
More on Capital Research Global Investors
FAQ
How long has Capital Research Global Investors held ABBV?
Capital Research Global Investors has disclosed ABBV holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Capital Research Global Investors's current position in ABBV?
As of Q3 2026, Capital Research Global Investors holds 31.12M shares of ABBV (ABBVIE INC), valued at $8.14B, representing 1.17% of its reported portfolio and ranking #20.
Has Capital Research Global Investors been buying or selling ABBV?
In the latest 13F filing (Q3 2026), Capital Research Global Investors increased its position in ABBV. The position peaked in Q3 2026 at 31.12M shares.
Which other funds hold ABBV?
Other major institutional holders of ABBV include Vanguard Group, BlackRock Inc, VANGUARD CAPITAL MANAGEMENT LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.